StockData

Insmed vs Kiniksa Pharmaceuticals International

INSM and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and KNSA compare

Insmed is the larger company, worth 1.8 times as much as Kiniksa Pharmaceuticals International ($26.7B against $14.9B).

Insmed grew revenue faster over the last twelve months (240% versus 58.2% for Kiniksa Pharmaceuticals International).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −39.9% at Insmed.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMKNSA
Size and price
Market cap$26.7B$14.9B
Share price$121.86$95.11
Change, 1 year−36.9%136%
Change, 5 years321%716%
Beta (5Y)0.840.15
Employees1,664366
StockData Score
Total score814 (better)
Valuation score00
Growth score34 (better)
Performance score24 (better)
Health score36 (better)
Dividend score00
Valuation
P/E–73.2×
P/S17.6×15.8× (better)
P/B36.8×21.0× (better)
EV/EBITDA–109×
P/FCF–75.8×
FCF yield−2.3%1.3% (better)
Fair value$61.10$16.72
Margin of safety−99.5% (better)−469%
Growth
Revenue growth (TTM)240% (better)58.2%
Revenue growth, 5Y average29.8%–
Net income growth (TTM)–205%
EPS growth (TTM)–189%
Profitability
Gross margin84.4%90.2% (better)
Operating margin−37.1%13.8% (better)
Net margin−39.9%11.6% (better)
FCF margin−41.3%20.8% (better)
Return on equity−72.5%17.6% (better)
Return on invested capital–60.2%
Financial health
Debt / equity0.76 (better)0.00
Interest coverage−6.9×–
Current ratio2.863.91 (better)
Altman Z-score7.4234.40 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%29.9%
Held by insiders0.89%5.1%
Insider net buying, 12 months−$133M−$122M (better)
Superinvestors holding1–
Short interest, % of float6.5%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.